On April 8, 2020, nine departments including the Guangdong Provincial Department of Science and Technology, Guangdong Provincial Development and Reform Commission, Guangdong Provincial Department of Industry and Information Technology, Guangdong Provincial Department of Finance, Guangdong Provincial Health Commission, Guangdong Provincial Medical Security Bureau, Guangdong Provincial Local Financial Supervision and Administration Bureau, Guangdong Provincial Administration of Traditional Chinese Medicine, and Guangdong Provincial Food and Drug Administration jointly issued “Several Policies and Measures on Promoting the Innovation and Development of Biomedicine” (hereinafter referred to as the “Measures”), is committed to improving the original innovation capabilities and international competitiveness of biomedicine, promoting high-quality development of biomedical technology and industry, and improving biosafety governance capabilities.
Shenzhen, as a city of high-tech innovation, has always been at the forefront of the country in the development of biomedicine. On March 3 this year, the Shenzhen Municipal Government issued the “Guiding Opinions on Promoting the Cluster Development of the Biopharmaceutical Industry in Shenzhen” and two supporting documents, “Several Measures in Shenzhen to Promote the Cluster Development of the Biopharmaceutical Industry”,It clearly mentions the development of stem cell therapy, immunotherapy, gene therapy and other biotherapeutic technologies; and actively promotes the transformation of results and supports the establishment of a somatic cell therapy clinical research and transformation application platform.
Cell therapy technology will be one of the most important ways for humans to treat diseases in the future. At present, we have also opened formal channels for new stem cell drug research and clinical research filings. As a leader in the cell industry,Beike Biotechnology has always insisted on taking technological innovation and quality as the core and lifeline of the company’s development, insisting on promoting high-quality development of the domestic cell industry through R&D and standardization, enhancing the initiative and voice of my country’s cell industry in the international cell industry, and applying cell research results to the treatment of major diseases as soon as possible. In 2019, Beike Bio’s research result “Key technological innovation and clinical application of allogeneic mesenchymal stem cells in the treatment of refractory lupus erythematosus” won the National Technology Invention Award; in 2020, in the fight against the new coronavirus pneumonia epidemic, Beike Bio and Shenzhen The “Clinical Research on Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe Pneumonia Caused by Coronavirus” project jointly submitted by Shenzhen Third People’s Hospital was approved by the Guangdong Provincial Department of Science and Technology for the 2020 Guangdong Provincial Emergency Response Project for the Prevention and Control of Novel Coronavirus.